Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus EMFLAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus EMFLAZA.
CORTONE vs EMFLAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Category C
Category C
Corticosteroid
Corticosteroid